The antioxidant effect of DL-alpha-lipoic acid on copper-induced acute hepatitis in Long-Evans Cinnamon (LEC) rats.
The Long-Evans Cinnamon (LEC) rats, due to a genetic defect, accumulate excess copper (Cu) in the liver in a manner similar to patients with Wilson's disease and spontaneously develop acute hepatitis with severe jaundice. In this study we examined the protective effect of DL-alpha-Lipoic acid (LA) against acute hepatitis in LEC rats. LA was administered to LEC rats by gavage in doses of 10, 30 and 100 mg/kg five times per week, starting at 8-weeks-old and continuing till 12-weeks-old. Although LA had little effect against the increases in serum transaminase activities, it suppressed the loss of body weight and prevented severe jaundice in a dose-dependent manner. Antioxidant system analyses in liver showed that LA treatment significantly suppressed the inactivations of catalase and glutathione peroxidase, and the induction of heme oxygenase-1, an enzyme which is inducible under oxidative stress. Furthermore, LA showed dose-dependent suppressive effect against increase in nonheme iron contents of both cytosolic and crude mitochondrial fractions in a dose-dependent manner. Although at the highest dose, LA slightly suppressed the accumulation of Cu in crude mitochondrial fraction, it had no effect on the accumulation of Cu in cytosolic fraction. While LA completely suppressed the increase in lipid peroxidation (LPO) in the microsomal fraction at the highest dose, the suppressive effect against LPO in crude mitochondrial fractions was slight. From these results, it is concluded that LA has antioxidant effects at the molecular level against the development of Cu-induced hepatitis in LEC rats. Moreover, mitochondrial oxidative damage might be involved in the development of acute hepatitis in LEC rats.
Yamamoto
H
H
Medicinal Safety Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Watanabe
T
T
Mizuno
H
H
Endo
K
K
Fukushige
J
J
Hosokawa
T
T
Kazusaka
A
A
Fujita
S
S
D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003300:Copper / Q000378:metabolism / Q000633:toxicity*; D003600:Cytosol / Q000187:drug effects / Q000201:enzymology; D004435:Eating / Q000187:drug effects; D004798:Enzymes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1; D006520:Hepatitis, Animal / Q000139:chemically induced* / Q000188:drug therapy*; D007501:Iron / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D011506:Proteins / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D020332:Rats, Inbred LEC; D017208:Rats, Wistar; D008063:Thioctic Acid / Q000008:administration & dosage / Q000494:pharmacology*
D000975:Antioxidants; D004798:Enzymes; D011506:Proteins; D008063:Thioctic Acid; D003300:Copper; D007501:Iron; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1